>DaxServer: Add back cat per discussion WP:TCAT using Pywikibot category add

2021-08-22T15:25:26Z

Add back cat per discussion WP:TCAT using Pywikibot category add

New page

{{Multiple issues|
{{COI|date=March 2015}}
{{Orphan|date=September 2018}}
}}

{{Use dmy dates|date=May 2018}}
{{Use Indian English|date=May 2018}}

{{Infobox company
| name = Granules India Ltd.
| logo = Granules India logo.svg
| type = [[Public company|Public]]
| traded_as = {{BSE|532482}} {{NSE|GRANULES}}
| industry = [[Pharmaceutical company|Pharmaceuticals]]
| foundation = 1984
| founder = Mr. Krishna Prasad Chigurupati
| location = [[Hyderabad (India)|Hyderabad]], [[India]]
| area_served = Worldwide
| key_people = Krishna Prasad Chigurupati ([[Chairman|CMD]]) Harsha Chigurupati ([[Executive director|ED]]) Sandeep Neogi ([[CFO]]) GSR Prasad([[Chief operating officer|COO]]) Priyanka Chigurupati ([[Executive Director|ED]])
| products = [[Paracetamol]], [[Ibuprofen]], [[Methocarbamol]], [[Metformin]], [[Guaifenesin]], etc.
| revenue = FY 2018–19 [[Indian rupee|INR]] 2,279 [[Crore]]
| num_employees = 2789
| profit = FY 2018–19 [[Indian rupee|INR]] 236 [[Crore]]
| homepage = [http://www.granulesindia.com/ www.granulesindia.com]
}}

'''Granules India Limited''' is an Indian [[pharmaceutical]] manufacturing company based in [[Hyderabad (India)|Hyderabad]], [[India]]. Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and rest of the world markets. Granules India Limited entered '''CRAMS segment''', which focuses on contract research and manufacturing.<ref>{{cite news|url=http://www.moneycontrol.com/news/business/granules-india-signs-dealmatchland-pty-ltd_270194.html|title=Granules India signs deal with Matchland Pty Ltd}}</ref><ref>{{cite news|url=http://www.thehindubusinessline.com/2007/05/10/stories/2007051001371700.htm|title=Granules India| date=10 May 2007|work=Moneycontrol.com|accessdate=10 December 2009}}</ref>

==History==
Granules India was formed in 1984 as Triton Laboratories. Triton produced Paracetamol API at its Bonthapally factory on the outskirts of Hyderabad.<ref>{{cite web|url=https://www.zaubacorp.com/company/TRITON-LABORATORIES-NTD/U24231TG1984PLC004914 | title=Triton Laboratories Ltd Company info}}</ref> Triton scientists found a more efficient way to produce the Paracetamol API, which led to lower capital and raw material requirements.{{citation needed|date=March 2015}} In 1987, Triton became the only Indian company aside from Dr. Reddy's Laboratories to export pharmaceutical products to the U.S.{{citation needed|reason=not in cited reference|date=March 2015}}

Though Triton was growing as an API manufacturer, management decided it could create a value added version of its product.{{citation needed|date=March 2015}} In order to distinguish itself from competitors, Triton management pioneered the concept of manufacturing and selling in bulk granulated Paracetamol, also known as direct compressible grade material (DC), or "PFI".{{citation needed|date=March 2015}} In 1990, it opened its second manufacturing facility at Jeedimetla to produce multiple APIs.

In 1991,<ref name="Granulesindia.com">{{cite web |url=http://www.granulesindia.com/Milestones.aspx |title=Granules India Limited – About Us – Milestones |publisher=Granulesindia.com |date= |accessdate=2010-09-30 |archive-url=https://web.archive.org/web/20100717135916/http://www.granulesindia.com/Milestones.aspx |archive-date=17 July 2010 |url-status=dead }}</ref> management set up a new entity, which was incorporated as Granules India Limited. Soon after Granules applied the PFI concept to other APIs, set up a PFI facility at Jeedimetla and began exporting the material to various markets including the U.S., Germany and Australia.<ref>{{cite news|url=http://www.moneycontrol.com/news/business/granules-ties-upgsk-healthcare-rd_262764.html|title=Granules ties up with GSK Healthcare R&D}}</ref>

In 1995,<ref name="Granulesindia.com"/> Granules became a public company, after having [[initial public offering]]s on the Bombay and Hyderabad Stock Exchanges.<ref>{{cite news|url=http://www.business-standard.com/india/storypage.php?autono=257912|title=Granules, Amneal Pharma get FDA nod|date=2 August 2006|work=Business Standard|accessdate=10 December 2009}}</ref>

In 2013, Granules India acquires Auctus Pharma for Rs 120 crore.<ref>{{Cite web|url=https://www.businesstoday.in/current/deals/granules-india-acquires-auctus-pharma/story/200299.html|title=Granules India acquires Auctus Pharma for Rs 120 crore|website=www.businesstoday.in|access-date=2020-02-10}}</ref>

In 2016, Granules India commissioned a new state of the art manufacturing unit that hosts facilities for Oncology and High Potent APIs. This new plant is located in [[Visakhapatnam district|Visakhapatnam]].

In order to secure API for its Ibuprofen PFI, Granules formed a joint-venture with Hubei Biocause Heilen Pharmaceutical to create Granules Biocause in Wuhan, China. Granules India Limited on announced its intention to divest its entire equity shareholding in Granules Biocause Pharmaceuticals Co. Ltd. by selling its stake to joint venture partner.<ref>{{cite web|url=http://www.in-pharmatechnologist.com/Materials-Formulation/Granules-India-takes-stake-in-Chinese-firm |title=Granules India takes stake in Chinese firm |publisher=In-pharmatechnologist.com |date= |accessdate=2010-09-30}}</ref>

==Infrastructure==
Granules has seven manufacturing facilities; six are in India while the seventh is through a joint-venture with Hubei Biocase in Wuhan, China. The company also has two research centres, at Hyderabad and Pune.

[[File:Granules GGP plant1.jpg|thumb|right|Gagillapur Plant]]

The Gagillapur facility is located near Hyderabad and has a Finished Dosage block, a PFI block and a research & development facility.{{citation needed|date=May 2018}}

Granules commissioned the world's single largest PFI plant in Gagillapur in August 2003 with a batch size of 6 MT and an annual capacity of 7,200 MT per annum. The plant received its US FDA approval within six months of commissioning.{{citation needed|date=May 2018}}

==See also==
*[[Pharmaceutical industry in India]]

==References==
{{Reflist}}8. https://health.economictimes.indiatimes.com/news/pharma/granules-india-to-divest-its-stake-in-its-joint-venture-located-in-china/71596498

[[Category:Pharmaceutical companies of India]]
[[Category:Manufacturing companies based in Hyderabad, India]]
[[Category:Pharmaceutical companies established in 1984]]
[[Category:Indian companies established in 1984]]
[[Category:1984 establishments in Andhra Pradesh]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]

Granules India Limited - Revision history

>DaxServer: Add back cat per discussion WP:TCAT using Pywikibot category add